Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs

Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188481. doi: 10.1016/j.bbcan.2020.188481. Epub 2020 Nov 17.

Abstract

One of the main problems with the treatment of metastatic prostate cancer is that, despite an initial positive response, the majority of patients develop resistance and progress. In particular, the resistance to docetaxel, the gold standard therapy for metastatic prostate cancer since 2010, represents one of the main factors responsible for the failure of prostate cancer therapy. According to the present knowledge, different processes contribute to the appearance of docetaxel resistance and non-coding RNA seems to play a relevant role in them. In this review, a comprehensive overview of the miRNA network involved in docetaxel resistance is described, highlighting the pathway/s affected by their activity.

Keywords: Docetaxel resistance; Drug resistance; Prostate cancer; Taxane; miRNAs.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Docetaxel / adverse effects
  • Docetaxel / therapeutic use*
  • Drug Resistance, Neoplasm / genetics*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Male
  • MicroRNAs / genetics
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / pathology
  • Taxoids / adverse effects
  • Taxoids / therapeutic use

Substances

  • Antineoplastic Agents
  • MicroRNAs
  • Taxoids
  • Docetaxel